Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Profit After Tax (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of Profit After Tax readings, the most recent being -$94535.0 for Q1 2026.

  • On a quarterly basis, Profit After Tax fell 1207.49% to -$94535.0 in Q1 2026 year-over-year; TTM through Jan 2026 was -$102807.0, a 68.92% increase, with the full-year FY2025 number at -$100463.0, up 87.08% from a year prior.
  • Profit After Tax hit -$94535.0 in Q1 2026 for Pharma-Bio Serv, down from $403927.0 in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $460466.0 in Q3 2023 to a low of -$381782.0 in Q3 2024.
  • Median Profit After Tax over the past 5 years was $240027.0 (2022), compared with a mean of $93686.1.
  • Biggest five-year swings in Profit After Tax: soared 854.73% in 2024 and later tumbled 1207.49% in 2026.
  • Pharma-Bio Serv's Profit After Tax stood at $341640.0 in 2022, then plummeted by 113.8% to -$47148.0 in 2023, then soared by 854.73% to $355838.0 in 2024, then rose by 13.51% to $403927.0 in 2025, then tumbled by 123.4% to -$94535.0 in 2026.
  • The last three reported values for Profit After Tax were -$94535.0 (Q1 2026), $403927.0 (Q4 2025), and -$313877.0 (Q3 2025) per Business Quant data.